Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any muscular dystrophy-dystroglycanopathy, type A in which the cause of the disease is a mutation in the POMK gene.
Features include always present findings: Type II lissencephaly, Hydrocephalus, Progressive muscle deterioration (muscular dystrophy), and Severe global developmental delay and others; and sometimes findings: Hypoplasia of the brainstem, Seizure, Agenesis of corpus callosum, and Cerebellar hypoplasia and others. 30 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Poor speech, Hypoplasia of the brainstem, Seizure |
Muscles | 4 | Flexion contracture, Progressive muscle deterioration (muscular dystrophy), Neonatal hypotonia |
Eyes | 3 | Cataract, Retinal degeneration, Visual impairment |
Head and neck | 2 | Progressive microcephaly, Microcephaly |
Lab test results | 1 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration) |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Digestive system | 1 | Feeding difficulties |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Pregnancy and birth | 1 | Neonatal hypotonia |
Lungs and breathing | 1 | Difficulty breathing due to muscle weakness (respiratory insufficiency due to muscle weakness) |
POMK function has not been fully characterized.
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12 is associated with mutations in the POMK gene on chromosome 8.
Genetic testing for POMK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12.
5 publications have been identified in PubMed for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12. Research spans Review / Meta-Analysis (60%), Diagnostic / Biomarker (20%), and Clinical Trial Publication (20%).
Rahmuni Y (2026). [PMID: 41742649](https://pubmed.ncbi.nlm.nih.gov/41742649/). *Mol Genet Genomic Med*. [Diagnostic / Biomarker]
Gandoy-Fieiras N (2025). [PMID: 40993721](https://pubmed.ncbi.nlm.nih.gov/40993721/). *Orphanet J Rare Dis*. [Review / Meta-Analysis]
Murakami T (2025). [PMID: 40814256](https://pubmed.ncbi.nlm.nih.gov/40814256/). *Neuropsychopharmacol Rep*. [Clinical Trial Publication]
Sharaf-Eldin W (2025). [PMID: 39998573](https://pubmed.ncbi.nlm.nih.gov/39998573/). *J Mol Neurosci*. [Review / Meta-Analysis]
Yurchenco PD (2024). [PMID: 38825010](https://pubmed.ncbi.nlm.nih.gov/38825010/). *J Biol Chem*. [Review / Meta-Analysis]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:36 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center